title: Glucose availability is a decisive factor for Nrf2-mediated gene expression.
abstract: Activation of the transcription factor Nrf2 (nuclear factor-erythroid 2-related factor 2) is one of the major cellular defense lines against oxidative and xenobiotic stress, but also influences genes involved in lipid and glucose metabolism. It is unresolved whether the cytoprotective and metabolic responses mediated by Nrf2 are connected or separable events in non-malignant cells. In this study we show that activation of Nrf2, either by the small molecule sulforaphane or knockout of the Nrf2 inhibitor Keap1, leads to increased cellular glucose uptake and increased glucose addiction in fibroblasts. Upon Nrf2 activation glucose is preferentially metabolized through the pentose phosphate pathway with increased production of NADPH. Interference with the supply of glucose or the pentose phosphate pathway and NADPH generation not only hampers Nrf2-mediated detoxification of reactive oxygen species on the enzyme level but also Nrf2-initiated expression of antioxidant defense proteins, such as glutathione reductase and heme-oxygenase1. We conclude that the Nrf2-dependent protection against oxidative stress relies on an intact pentose phosphate pathway and that there is crosstalk between metabolism and detoxification already at the level of gene expression in mammalian cells.
authors.affiliation: Department of Pharmacognosy, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria.
authors.forename: Elke H
authors.initials: EH
authors.lastname: Heiss
authors.forename: Daniel
authors.initials: D
authors.lastname: Schachner
authors.forename: Kristin
authors.initials: K
authors.lastname: Zimmermann
authors.forename: Verena M
authors.initials: VM
authors.lastname: Dirsch
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D002478:Cells, Cultured; D003598:Cytoskeletal Proteins / Q000235:genetics / Q000378:metabolism*; D005347:Fibroblasts / Q000378:metabolism; D055785:Gene Knockdown Techniques; D005947:Glucose / Q000378:metabolism*; D017879:Isothiocyanates / Q000494:pharmacology*; D000072019:Kelch-Like ECH-Associated Protein 1; D051379:Mice; D009249:NADP / Q000378:metabolism; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D018384:Oxidative Stress; D010427:Pentose Phosphate Pathway; D013454:Sulfoxides
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D003598:Cytoskeletal Proteins; D017879:Isothiocyanates; C117301:Keap1 protein, mouse; D000072019:Kelch-Like ECH-Associated Protein 1; D051267:NF-E2-Related Factor 2; C495636:Nfe2l2 protein, mouse; D013454:Sulfoxides; D009249:NADP; C016766:sulforaphane; D005947:Glucose
keywords: 3BP, 3-bromopyruvate; ATP, adenosine triphosphate; DCF, dichloroflourescein; DHEA, dehydroandrostendione; DMSO, dimethylsulfoxide; G6PD, glucose 6-phosphate dehydrogenase; GR, glutathione reductase; Glucose addiction; Glut1, glucose transporter 1; HO-1, heme oxygenase-1; Keap1, Kelch-like ECH-associated protein1; MEF, mouse embryonic fibroblasts; Maf, small masculoaponeurotic fibrosarcoma; NADP, nicotine adenine dinucleotide phosphate; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2; Nrf2, nuclear factor-erythroid 2-related factor 2; OXPHOS, oxidative phosphorylation; PBS, phosphate buffered saline; PPP, pentose phosphate pathway; ROS detoxification; ROS, reactive oxygen species; SFN, sulforaphane; WT, wild type; ctrl, control
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:89-116
references.pmid: 16968214
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):655-64
references.pmid: 18281592
references.citation: Carcinogenesis. 2009 Jun;30(6):1024-31
references.pmid: 19386581
references.citation: J Pharmacol Exp Ther. 2010 Apr;333(1):140-51
references.pmid: 20086057
references.citation: J Biol Chem. 2010 Mar 19;285(12):9292-300
references.pmid: 20089859
references.citation: Antioxid Redox Signal. 2011 Jul 15;15(2):311-24
references.pmid: 21348809
references.citation: Mol Cell Biol. 2007 Oct;27(20):7188-97
references.pmid: 17709388
references.citation: Trends Mol Med. 2012 Jun;18(6):337-47
references.pmid: 22578879
references.citation: Adv Pharmacol. 2012;63:43-79
references.pmid: 22776639
references.citation: Biochem Pharmacol. 2013 Mar 15;85(6):705-17
references.pmid: 23219527
references.citation: Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):99-106
references.pmid: 16487042
references.citation: Cancer Cell. 2012 Jul 10;22(1):66-79
references.pmid: 22789539
references.citation: J Med Chem. 2012 May 10;55(9):4431-45
references.pmid: 22506561
references.citation: Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44
references.pmid: 19698707
references.citation: Antioxid Redox Signal. 2012 May 15;16(10):1061-70
references.pmid: 22149292
references.citation: Mol Cell Biol. 2013 Aug;33(15):2996-3010
references.pmid: 23716596
references.citation: Genes Dev. 2010 Dec 15;24(24):2717-22
references.pmid: 21159812
references.citation: Diabetologia. 2011 Apr;54(4):922-34
references.pmid: 21161163